GlaxoSmithKline Q3 Profit Dips 72%, Revenue Up - Business News
By Rediff Money Desk, NEWDELHI Feb 12, 2024 18:37
GlaxoSmithKline Pharmaceuticals's net profit fell 72% to Rs 46 crore in Q3, while revenue increased to Rs 833 crore. The company is focusing on new categories like adult immunisation.
![GlaxoSmithKline Q3 Profit Dips 72%, Revenue Up - Business News](https://im.rediff.com/money/2016/mar/07pharma.jpg)
New Delhi, Feb 12 (PTI) GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit declined 72 per cent to Rs 46 crore for the December quarter.
The drug firm had reported a net profit of Rs 165 crore in the year-ago period.
Total income increased to Rs 833 crore for the third quarter of the current fiscal as compared with Rs 826 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement.
"We remain committed to new category development in areas like adult immunisation with products like Shingrix to make a positive impact to the lives of the patients in India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said.
The company would continue to drive operational efficiency and explore new innovative solutions, including omnichannel strategy, to expand reach and coverage to the target segments, he added.
Shares of the drugmaker declined 1.91 per cent to Rs 2,334.20 apiece on the BSE on Monday.
The drug firm had reported a net profit of Rs 165 crore in the year-ago period.
Total income increased to Rs 833 crore for the third quarter of the current fiscal as compared with Rs 826 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement.
"We remain committed to new category development in areas like adult immunisation with products like Shingrix to make a positive impact to the lives of the patients in India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said.
The company would continue to drive operational efficiency and explore new innovative solutions, including omnichannel strategy, to expand reach and coverage to the target segments, he added.
Shares of the drugmaker declined 1.91 per cent to Rs 2,334.20 apiece on the BSE on Monday.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![Navi Mumbai...](https://im.rediff.com/80-80/money/2021/jun/10navi-mumbai-airport7.jpg)
Navi Mumbai Airport ILS Signal Testing Begins
The Airports Authority of India (AAI) has begun ILS signal testing at the...
![Air India VRS for...](https://im.rediff.com/80-80/money/2020/sep/09tata-vistara-3.jpg)
Air India VRS for Non-Flying Staff Ahead of...
Air India has announced a voluntary retirement scheme (VRS) and voluntary separation...
Fisher Groups Oppose WTO Fisheries Subsidy Talks
Small-scale fisher groups from India, Indonesia, and Bangladesh demand WTO keep...